From the quarterly (viewable on Bell Direct).
"CASH FLOWS
The closing cash balance at 31 December 2018was $12M, which has increased by $5.7m compared to 30 September2018 and includes the following:-Operating cash outflow of $5.8m, including an ongoing investment in Research &Development of $1.0m. -
Net cash inflow from financing activities of $11.7m, driven by the additional shares taken up by the market under the rights issue (net of transaction costs) partly offset by the repayment of the $5.0M unsecured loan with Star Bright.
The operating cash outflows for the quarter were $0.5m lower than the estimate provided at October2018, mainly due to timing of working capital payments partly offset by additional operational consultancy costs incurred.
The estimated quarter one 2019 operating cash outflow is $15.5m –refer section 9 below for details."
I struggle to see this as good news.
?
P
- Forums
- ASX - By Stock
- AVR
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-2
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.68 |
Change
-0.320(2.67%) |
Mkt cap ! $246.9M |
Open | High | Low | Value | Volume |
$11.57 | $11.81 | $11.42 | $152.5K | 13.10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 116 | $11.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.68 | 188 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 116 | 11.500 |
1 | 1000 | 11.400 |
1 | 2 | 11.260 |
1 | 8 | 11.220 |
2 | 1045 | 11.200 |
Price($) | Vol. | No. |
---|---|---|
11.680 | 188 | 1 |
11.700 | 1351 | 1 |
11.900 | 1000 | 1 |
12.000 | 4817 | 1 |
12.400 | 198 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online